TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study
ABSTRACT Background The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis. Aims Given the changes in the entities included in each subtype under t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70533 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589770761437184 |
|---|---|
| author | Hao Xing Delin Liu Junlin Li Yulu Ge Xiaopeng Guo Wenlin Chen Dachun Zhao Yixin Shi Yilin Li Yaning Wang Yuekun Wang Yu Xia Jiaming Wu Tingyu Liang Hai Wang Qianshu Liu Shanmu Jin Tian Qu Siying Guo Huanzhang Li Tianrui Yang Kun Zhang Yu Wang Wenbin Ma |
| author_facet | Hao Xing Delin Liu Junlin Li Yulu Ge Xiaopeng Guo Wenlin Chen Dachun Zhao Yixin Shi Yilin Li Yaning Wang Yuekun Wang Yu Xia Jiaming Wu Tingyu Liang Hai Wang Qianshu Liu Shanmu Jin Tian Qu Siying Guo Huanzhang Li Tianrui Yang Kun Zhang Yu Wang Wenbin Ma |
| author_sort | Hao Xing |
| collection | DOAJ |
| description | ABSTRACT Background The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis. Aims Given the changes in the entities included in each subtype under the new classification, this research investigated the distribution, prognostic value, and correlations with other molecular alterations of TERTp mutation in different subgroups under this latest classification. Methods All glioma patients admitted to Peking Union Medical College Hospital for surgical resection or biopsy from 2011 to 2022 were included. Samples were analyzed for TERTp mutation and 59 other gene alterations and chromosome copy number variations. Results A total of 207 patients were included. The occurrence of TERTp mutations varied with percentages of 4.55%, 100%, and 77.92% in astrocytoma, oligodendroglioma, and glioblastoma, respectively. 65% of all adult‐type glioma patients and 42.6% of IDH‐wildtype histology grade 2 or 3 patients were TERTp‐mutant. Survival analysis showed that TERTp mutation was a predictor of better prognosis in IDH‐mutant grade 2 gliomas (median OS (mOS): not reached (NA) (95% CI: NA–NA) vs. 75.9 (95% CI: 55.4–NA) months, HR = 0.077 (95% CI: 0.01–0.64), p = 0.003), while poor OS was associated with all Grade 4 gliomas (mOS: 17.5 (95% CI: 12.6–24.2) vs. 40.5 (95% CI: 24.4–83.8) months, HR = 2.014 (95% CI: 1.17–3.47), p = 0.01) and all IDH‐wildtype histology grade 2 or 3 gliomas (median OS: 12.6 (95% CI: 11–24.2) vs. 83.8 (95% CI: 35.2–NA) months, HR = 3.768 (95% CI: 1.83–7.78), p < 0.001). Moreover, TERTp mutation tended to co‐occur with EGFR, KRAS, and MET in glioblastoma. In the IDH‐mutant subgroup, it tended to co‐occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions. |
| format | Article |
| id | doaj-art-6da37eff475c4b8ebee7a802c669e0ec |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-6da37eff475c4b8ebee7a802c669e0ec2025-01-24T08:46:07ZengWileyCancer Medicine2045-76342025-01-01142n/an/a10.1002/cam4.70533TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World StudyHao Xing0Delin Liu1Junlin Li2Yulu Ge3Xiaopeng Guo4Wenlin Chen5Dachun Zhao6Yixin Shi7Yilin Li8Yaning Wang9Yuekun Wang10Yu Xia11Jiaming Wu12Tingyu Liang13Hai Wang14Qianshu Liu15Shanmu Jin16Tian Qu17Siying Guo18Huanzhang Li19Tianrui Yang20Kun Zhang21Yu Wang22Wenbin Ma23Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaABSTRACT Background The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis. Aims Given the changes in the entities included in each subtype under the new classification, this research investigated the distribution, prognostic value, and correlations with other molecular alterations of TERTp mutation in different subgroups under this latest classification. Methods All glioma patients admitted to Peking Union Medical College Hospital for surgical resection or biopsy from 2011 to 2022 were included. Samples were analyzed for TERTp mutation and 59 other gene alterations and chromosome copy number variations. Results A total of 207 patients were included. The occurrence of TERTp mutations varied with percentages of 4.55%, 100%, and 77.92% in astrocytoma, oligodendroglioma, and glioblastoma, respectively. 65% of all adult‐type glioma patients and 42.6% of IDH‐wildtype histology grade 2 or 3 patients were TERTp‐mutant. Survival analysis showed that TERTp mutation was a predictor of better prognosis in IDH‐mutant grade 2 gliomas (median OS (mOS): not reached (NA) (95% CI: NA–NA) vs. 75.9 (95% CI: 55.4–NA) months, HR = 0.077 (95% CI: 0.01–0.64), p = 0.003), while poor OS was associated with all Grade 4 gliomas (mOS: 17.5 (95% CI: 12.6–24.2) vs. 40.5 (95% CI: 24.4–83.8) months, HR = 2.014 (95% CI: 1.17–3.47), p = 0.01) and all IDH‐wildtype histology grade 2 or 3 gliomas (median OS: 12.6 (95% CI: 11–24.2) vs. 83.8 (95% CI: 35.2–NA) months, HR = 3.768 (95% CI: 1.83–7.78), p < 0.001). Moreover, TERTp mutation tended to co‐occur with EGFR, KRAS, and MET in glioblastoma. In the IDH‐mutant subgroup, it tended to co‐occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions.https://doi.org/10.1002/cam4.70533adult‐type diffuse gliomaglioma classificationmolecular subgroupsprognosisTERT promoter mutation |
| spellingShingle | Hao Xing Delin Liu Junlin Li Yulu Ge Xiaopeng Guo Wenlin Chen Dachun Zhao Yixin Shi Yilin Li Yaning Wang Yuekun Wang Yu Xia Jiaming Wu Tingyu Liang Hai Wang Qianshu Liu Shanmu Jin Tian Qu Siying Guo Huanzhang Li Tianrui Yang Kun Zhang Yu Wang Wenbin Ma TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study Cancer Medicine adult‐type diffuse glioma glioma classification molecular subgroups prognosis TERT promoter mutation |
| title | TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study |
| title_full | TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study |
| title_fullStr | TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study |
| title_full_unstemmed | TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study |
| title_short | TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study |
| title_sort | tertp mutation and its prognostic value in glioma patients under the 2021 who classification a real world study |
| topic | adult‐type diffuse glioma glioma classification molecular subgroups prognosis TERT promoter mutation |
| url | https://doi.org/10.1002/cam4.70533 |
| work_keys_str_mv | AT haoxing tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT delinliu tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT junlinli tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yuluge tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT xiaopengguo tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT wenlinchen tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT dachunzhao tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yixinshi tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yilinli tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yaningwang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yuekunwang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yuxia tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT jiamingwu tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT tingyuliang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT haiwang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT qianshuliu tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT shanmujin tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT tianqu tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT siyingguo tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT huanzhangli tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT tianruiyang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT kunzhang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT yuwang tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy AT wenbinma tertpmutationanditsprognosticvalueingliomapatientsunderthe2021whoclassificationarealworldstudy |